

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): **July 23, 2018**

---

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**0-19731**  
(Commission  
File Number)

**94-3047598**  
(I.R.S. Employer  
Identification No.)

**333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA**  
(Address of principal executive offices)

**94404**  
(Zip Code)

**(650) 574-3000**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

## Section 5 – CORPORATE GOVERNANCE AND MANAGEMENT

### Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

- (a) Departure of Directors
- (b) Departure of Certain Officers

On July 25, 2018, Gilead Sciences, Inc. (“Gilead”) announced that John F. Milligan, Ph.D., has agreed to step down as Gilead’s President and Chief Executive Officer and will resign from Gilead’s Board of Directors on December 31, 2018 or, if earlier, when his successor is named and commences in the role. Dr. Milligan has agreed to continue to serve through such date, and thereafter will remain an employee to assist in transitional matters through February 28, 2019. Compensation arrangements in connection with Dr. Milligan’s transition and separation will be filed once they have been finalized.

John Martin, Ph.D., currently Gilead’s Chairman of the Board of Directors, has also informed the Board of Directors of his intent to step down from the Board at the time a new Chief Executive Officer is named.

## SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

### Item 9.01 Financial Statements and Exhibits

- (d) Exhibits

Exhibit Number	Description
99.1	<a href="#">Press Release, issued by Gilead Sciences, Inc. on July 25, 2018.</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GILEAD SCIENCES, INC.**  
(Registrant)

\_\_\_\_\_  
/s/ Brett A. Pletcher

Brett A. Pletcher  
EVP, General Counsel and Corporate Secretary

Date: July 26, 2018



**CONTACTS:** Sung Lee, Investors  
(650) 524-7792

Amy Flood, Media  
(650) 522-5643

**For Immediate Release**

**GILEAD SCIENCES ANNOUNCES CEO JOHN F. MILLIGAN TO STEP DOWN**

*— Dr. Milligan to Remain With Company Through Year End —*

**Foster City, Calif., July 25, 2018** — Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer after a 28-year career with the company. Dr. Milligan will remain in his current position through the end of the year, while the Board of Directors conducts a search to identify a successor.

“It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the Board and I have agreed it is a good time to turn the reins over to a new leader,” said Dr. Milligan. “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.”

“Today, Gilead has the right strategy in place to successfully execute on its mission of improving the lives of people with some of the world’s most serious diseases, led by a robust HIV franchise, an industry-leading cell therapy platform and a late-stage pipeline in NASH and inflammation,” commented John C. Martin, PhD, Chairman of the Board of Directors. “Moreover, we have the resources to continue investing in and expanding our strong R&D pipeline, which remains paramount to our success. We are excited about our growth potential, and intend to hire a CEO who will build on the foundation that John Milligan has put in place and execute on our ambitious goals for the future.”

“On behalf of the entire Board, I want to thank John Milligan for his countless contributions to Gilead over nearly 30 years, and commend him for operating throughout his career with the highest personal and professional integrity,” said John Cogan, PhD, Lead Independent Director, Gilead Sciences Board of Directors. “Given his longstanding dedication to Gilead, it is no surprise that John is committed to facilitating a seamless transition for all of our stakeholders, as we work to identify his successor.”

Dr. Milligan will also step down from the Gilead Board of Directors at the end of the year. Additionally, Dr. Martin has announced his intent to step down from the Board at the time a new CEO joins the company, having determined that this would be a natural transition point from his successive roles as CEO, Executive Chairman and Chairman.

The Company today also released its financial results for the second quarter 2018. As previously announced, at 5:00 p.m. Eastern Time, management will host a conference call to discuss financial results and provide a general business update.

-more-

Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA  
phone 650 574 3000 *facsimile* 650 578 9264

[www.gilead.com](http://www.gilead.com)

---

## **About Gilead Sciences**

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

## **Forward-Looking Statement**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

###

*For more information about Gilead at [www.gilead.com](http://www.gilead.com), follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.*